This Announcement and the Information Contained Herein Is Restricted and Is Not for Release, Publication or Distribution, in Whole or in Part, Directly or Indirectly, in, Into or from Australia, Japan or the Republic of South Africa or to Be Transmitted, Distributed to, or Sent by, Any National or Resident or Citizen of Any Such Countries or Any Other Jurisdiction in Which Such Release, Publication or Distribution May Contravene Local Securities Laws or Regulations Read More
Source link
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
Fujirebio is a diagnostics company with over 75 years of experience delivering innovative solutions to healthcare providers, pharmaceutical companies, and in vitro diagnostics (IVD) partners worldwide. Leveraging world-class expertise in…






